J. Beadle

发表

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial.

J. Oxford, Rob Lambkin-Williams, M. Zambon, 2009, Vaccine.

P166 The emerging role of airway clearance techniques in the treatment of interstitial lung disease

A. Devaraj, F. Chua, J. Beadle, 2016, Thorax.

329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab

Richard J. P. Brown, A. Stone, J. Beadle, 2020, Journal for ImmunoTherapy of Cancer.

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

R. Salazar, B. Champion, L. Paz-Ares, 2017, Journal of Immunotherapy for Cancer.

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

J. Machiels, R. Salazar, B. Champion, 2019, Journal of Immunotherapy for Cancer.

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

S. Anker, A. Coats, F. Jaisser, 2014, European heart journal.

Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia.

S. Anker, A. Coats, U. Mayer, 2013, International journal of cardiology.

The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats

S. Anker, A. Coats, S. von Haehling, 2013, Journal of cachexia, sarcopenia and muscle.

MT-102, A New Anabolic Catabolic Transforming Agent Improves Heart Function in a Rat Model of Cancer Cachexia

S. Anker, A. Coats, J. Springer, 2012 .

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

B. Champion, K. Fisher, A. Lieber, 2017, Molecular therapy oncolytics.

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

D. Ferguson, B. Champion, L. Seymour, 2016, Molecular therapy oncolytics.

Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)

S. Anker, S. von Haehling, K. Prabhash, 2016, Journal of cachexia, sarcopenia and muscle.

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

S. Anker, B. Kirwan, Shankar Vangipuram, 2011, Journal of cachexia, sarcopenia and muscle.

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

S. Anker, A. Coats, F. Jaisser, 2014, European heart journal.